Intravenous high‐dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta‐analysis of three trials

Resected stage IIB–IIIC malignant melanoma has a poor prognosis with a high risk of relapse and death. Treatment with adjuvant interferon alfa‐2b (IFN‐α‐2b) is associated with improved relapse‐free and overall survivals (OS), but the most appropriate dose and duration of treatment are unknown. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Malczewski, Agnieszka, Marshall, Andrea, Payne, Miranda J., Mao, Lili, Bafaloukos, Dimitrios, Si, Lu, Pectasides, Dimitrios, Fountzilas, George, Guo, Jun, Gogas, Helen, Middleton, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708899/
https://www.ncbi.nlm.nih.gov/pubmed/26645567
http://dx.doi.org/10.1002/cam4.563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708899/
https://www.ncbi.nlm.nih.gov/pubmed/26645567
http://dx.doi.org/10.1002/cam4.563

Ejemplares similares